Latest Recruitment News

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Optiscan Imaging Ltd has initiated Australia’s first intra-operative head and neck cancer imaging study using its advanced InVue® and InForm™ devices, aiming to enhance surgical precision and support FDA regulatory submissions.

APC Minerals Limited announces a $1.5 million capital raising through a placement and entitlement offer, alongside the planned exit of CEO Matthew Shackleton.

Entropy Neurodynamics has successfully administered its proprietary IV-infused psilocin, TRP-8803, to the first patient in a clinical trial targeting Binge Eating Disorder, marking a world first in neuropsychiatric treatment.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

Wide Open Agriculture shakes up its leadership with a new board appointment and plans to recruit a CEO experienced in scaling plant protein businesses, signaling a strategic push to globalise its lupin protein technology.

Dateline Resources reports strong progress on its Colosseum Gold-Rare Earth Project in California, buoyed by soaring gold prices and growing US investor interest. The company is advancing its feasibility study with construction planned post-completion.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

PeopleIN Group reported a challenging FY25 with revenue down 6.5% and EBITDA down 10%, yet strengthened its balance sheet through debt reduction and a strategic sale. The company is poised to capitalise on Queensland's infrastructure boom and Defence sector opportunities.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Lion Rock Minerals has kicked off a large-scale infill drilling program at its Minta Est project in Cameroon, focusing on high-value minerals including rutile, zircon, and rare-earth elements monazite and xenotime. This move builds on recent discoveries and a strategic partnership with Tronox Holdings.